|
The Board of Henderson Morley plc (“Henderson Morley” or “the Company”), the AIM listed drug discovery company, is pleased to announce that is has signed a Material Transfer Agreement and Option to License with AIM-listed Stem Cell Sciences plc (“SCS”). This agreement allows SCS to explore the use of HM’s L-particles and PREPS technology (Technology) in the design of unique stem cell based assays.
Stem cell based assays provide enormous benefit for discovering novel physiological processes, and are becoming an invaluable research tool for both academic & commercial research. Success from proof of concept studies will be followed by licensing of Henderson Morley’s Technology to SCS in a non-therapeutic field of stem cells.
SCS will determine whether marked L-particles can be used in the design of reporter assays using stem cells being differentiated into more specified cell fates, such as neural, fat or bone cells. When successful, opportunities to create a range of relevant and useful assays with long term revenue potential may emerge. Being able to study normal physiology will be a major plus for the assays developed.
Andrew Knight, Chairman of Henderson Morley said: “We are pleased to announce our first potential license using PREPS and L-particles, and are excited to be working in this new ground breaking area with Stem Cell Sciences, a company which has an international reputation of excellence in the field. The possibility of modifying stem cells in a way that has not been possible to date will be an important scientific milestone. This could provide an exciting near term commercial opportunity for Henderson Morley, and we will continue to seek more licensing partners using PREPS and L-particles as both drug delivery vehicles and vaccine candidates.”
Hugh Ilyine, VP & Chief Operating Officer of SCS plc added “SCS is a world leading supplier of stem cell based technologies for the research and bio-pharmaceutical industries. By adding to our stem cell a novel reporter gene expression technology we will continue the development of competitive biological discovery tools, and look forward to a fruitful working relationship with Henderson Morley”. |
